What's in Addpharma Inc.'s pipeline?

Addpharma Inc. has 71 drugs in our index: 1 marketed, 0 filed, 32 in Phase 3, 5 in Phase 2, 33 in Phase 1.

Which companies overlap with Addpharma Inc.'s portfolio?

Top competitors by shared drug class: Ahn-Gook Pharmaceuticals Co.,Ltd, GlaxoSmithKline, AstraZeneca, Organon and Co, Astellas Pharma Inc.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/addpharma-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Addpharma Inc. — Portfolio Competitive Intelligence Brief

Addpharma Inc. pipeline: 1 marketed, 0 filed, 32 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 32 Phase 3 5 Phase 2 33 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Ezetimibe/Rosuvastatin	Ezetimibe/Rosuvastatin	marketed	Cholesterol absorption inhibitor + HMG-CoA reductase inhibitor (statin combination)	NPC1L1 transporter (ezetimibe); HMG-CoA reductase (rosuvastatin)	Cardiovascular
AD-223C	AD-223C	phase 3	PD-1 inhibitor	PD-1	Oncology
AD-209	AD-209	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
AD-2021	AD-2021	phase 3	PI3K inhibitor	PI3K	Oncology
placebo of AD-2081	placebo of AD-2081	phase 3
AD-227B	AD-227B	phase 3	Serotonin receptor antagonist	5-HT2A	Psychiatry
AD-224A	AD-224A	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
AD-221C	AD-221C	phase 3	PD-1 inhibitor	PD-1	Oncology
AD-227C	AD-227C	phase 3	Serotonin receptor antagonist	5-HT2A receptor	Psychiatry
AD-221B	AD-221B	phase 3	PD-1 inhibitor	PD-1	Oncology
AD-227A	AD-227A	phase 3	Serotonin receptor agonist	5-HT2A receptor	Psychiatry
Placebo of AD-227C	Placebo of AD-227C	phase 3

Therapeutic area mix

Oncology · 11
Diabetes · 9
Psychiatry · 3
Cardiovascular · 2
Autoimmune diseases · 1
Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Ahn-Gook Pharmaceuticals Co.,Ltd · 4 shared drug classes
GlaxoSmithKline · 4 shared drug classes
AstraZeneca · 3 shared drug classes
Organon and Co · 3 shared drug classes
Astellas Pharma Inc · 2 shared drug classes
Balmoral Medical company · 2 shared drug classes
Applied Biology, Inc. · 2 shared drug classes
Ain Shams University · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Addpharma Inc.:

Cite this brief

Drug Landscape (2026). Addpharma Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/addpharma-inc. Accessed 2026-05-13.